The company PDL Pharma has abandoned its ulcerative colitis drug Nuvion (Visilizumab), citing lack of efficacy and an "inferior safety profile."
"The Fremont, Calif., company said preliminary results from a late-stage trial of Nuvion show the drug is not effective, and less safe than intravenous steroids alone. The company ended development of the drug."
source: www.forbes.com "Ahead of the Bell: PDL Biopharma Slides"
Notably, this drug was "pushed" in the CCFA's article describing the "benefits" of participating in clinical trials.
Some of the ethical issues regarding clinical trial recruitment may be found here.